Gadeta to Attend Upcoming Business and Investor Conferences
Utrecht, Netherlands and Boston, Mass., 4th May 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage
company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for
every cancer patient, today announces it will be attending the following conferences:
